PIAS4 and breast cancer: miR-210 is known to be involved in mechanisms related to anthracycline and taxane resistance, and its upregulation has been linked to poor prognosis in BC due to the targeting of the protein inhibitor of activated signal transducer and the activator of transcription 4 (PIAS4), which affects the sensitivity of BC chemotherapy and decreases apoptosis [118,119].